Advanced Solutions
for Advanced Pathology
CD21 (EP3093
†
)
Rabbit Monoclonal Antibody
Cat. No. Description
Volume
45275 IMPATH CD21 RTU R (EP3093)
50 Tests
44228 CD21 RTU R (EP3093)
7 ml Ready To Use
44478 CD21 0,1 R (EP3093)
100 µl liquid Concentrated
44479 CD21 1 R (EP3093)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic, Membranous
Control
Lymph Node, Tonsil
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
CD21 (also known as complement receptor 2 (CR2), C3d receptor, or EBV receptor) is a 140 kDa membrane protein on B-lymphocytes to which
the Epstein-Barr virus (EBV) binds during infection of these cells. The antigen is absent on T-lymphocytes, monocytes, and granulocytes.
Anti-CD21 is useful in the identification of follicular dendritic cell matrix found in normal lymph node and tonsillar tissue. This antibody also labels
follicular dendritic cell sarcomas. Anti-CD21 is valuable in differentiating follicular lymphoma with marginal zone differentiation from marginal
zone lymphoma with follicular involvement. It also plays a role in separating among nodular lymphocyte predominant Hodgkin lymphoma,
lymphocyte-rich classic Hodgkin lymphoma, and T-cell/histiocyte-rich B-cell lymphoma in combination with other B-cell and T-cell markers.
Lymph Node
CD21/CD35
CD68
S-100
CD1a
Lysozyme
Reactive Histiocytosis
-
+
-
-
+
Langerhans Histiocytosis
-
+
+
+
+
Sinus Histiocytosis with
Massive Lymphadenopathy
-
+
+
-
+
Follicular Dendritic Cell
Sarcoma
+
-
-
+/-
-
Dermatopathic
Lymphadenitis
-
-
+
+
+
Reference
1. Dillon KM, et al. J Clin Pathol. 2002 Oct; 55(10):791-4.
2. Pileri SA, et al. Histopathology. 2002; 41:1-29.
3. Kunihiko Maeda, et al. J Histochem Cytochem. 2002; 50:1475-1485.
4. Herrmann LM, et al. Am J Pathol. 2003; 162:1075-1081.
5. Biddle DA, et al. Modern Pathology. 2002; 15:50-58.
59
